Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable ATP-dependent RNA helicase DDX23 (DDX23) is a member of the DEAD box protein family characterized by the conserved Asp-Glu-Ala-Asp (DEAD) motif and functions as a putative RNA helicase[1][3][5]. DDX23 is a core component of the U5 small nuclear ribonucleoprotein (snRNP) complex and plays an essential role in nuclear pre-mRNA splicing by facilitating conformational changes in the spliceosome, particularly enabling the transition to the activated B complex[1][7]. Its phosphorylation by SRPK2 is critical for proper spliceosome assembly and for suppressing RNA:DNA hybrids (R-loops), thereby supporting genomic integrity[1]. DDX23 is also implicated in microRNA biogenesis, embryogenesis, spermatogenesis, and general RNA metabolism, with dysfunction linked to neurodevelopmental disorders (e.g., global developmental delay and seizures) and cancer, where it can regulate cancer-associated non-coding RNAs and serve as a candidate biomarker for disease progression[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX23 (DDX23).